Stereoselective effects of 3-hydroxybutyrate on glucose utilization of rat cardiomyocytes

Yih Chiao Tsai, Yu Ching Chou, An-Bang Wu, Chien-Ming Hu, Chau Yang Chen, Fu An Chen, Jen Ai Lee

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

In researches of ketone bodies, D-3-hydroxybutyrate (D-3HB) is usually the major one which has been investigated; in contrast, little attention has been paid to L-3-hydroxybutyrate (L-3HB), because of its presence in trace amounts, its dubious metabolism, and a lack of knowledge about its sources. In the present study we determined the distributions of enantiomers of 3-hydroxybutyrate (3HB) in rat brain, liver, heart, and kidney homogenates, and we found the heart homogenate contained an enriched amount of L-3HB (37.67 μM/mg protein) which generated a significant ratio of 66 / 34 (D / L). The ratio was altered to be 87 / 13 in the diabetic rat heart homogenate. We subsequently found this changed ratio of D / L-3HB may contribute to reduce glucose utilization in cardiomyocytes. Glucose utilization by cardiomyocytes with 5 mM of D-3HB was decreased to 61% of the control, but no interference was observed when D-3HB was replaced with L-3HB, suggesting L-3HB is not utilized for the energy fuel as other ketone bodies are. In addition, the reduced glucose utilization caused by D-3HB gradually recovered in a dose-dependent manner with administration of additional L-3HB. The results gave the necessity of taking L-3HB together with D-3HB into account with regard to glucose utilization, and L-3HB may be a helpful substrate for improving inhibited cardiac pyruvate oxidation caused by hyperketonemia.

Original languageEnglish
Pages (from-to)1385-1391
Number of pages7
JournalLife Sciences
Volume78
Issue number12
DOIs
Publication statusPublished - Feb 16 2006

Fingerprint

3-Hydroxybutyric Acid
Cardiac Myocytes
Rats
Glucose
Ketone Bodies
Enantiomers
Pyruvic Acid
Metabolism
Liver
Brain

Keywords

  • Cardiomyocytes
  • D-3-hydroxybutyrate
  • Glucose utilizaticon
  • L-3-hydroxybutyrate

ASJC Scopus subject areas

  • Pharmacology

Cite this

Stereoselective effects of 3-hydroxybutyrate on glucose utilization of rat cardiomyocytes. / Tsai, Yih Chiao; Chou, Yu Ching; Wu, An-Bang; Hu, Chien-Ming; Chen, Chau Yang; Chen, Fu An; Lee, Jen Ai.

In: Life Sciences, Vol. 78, No. 12, 16.02.2006, p. 1385-1391.

Research output: Contribution to journalArticle

Tsai, Yih Chiao ; Chou, Yu Ching ; Wu, An-Bang ; Hu, Chien-Ming ; Chen, Chau Yang ; Chen, Fu An ; Lee, Jen Ai. / Stereoselective effects of 3-hydroxybutyrate on glucose utilization of rat cardiomyocytes. In: Life Sciences. 2006 ; Vol. 78, No. 12. pp. 1385-1391.
@article{3eb1862221e34842a754b86872422c81,
title = "Stereoselective effects of 3-hydroxybutyrate on glucose utilization of rat cardiomyocytes",
abstract = "In researches of ketone bodies, D-3-hydroxybutyrate (D-3HB) is usually the major one which has been investigated; in contrast, little attention has been paid to L-3-hydroxybutyrate (L-3HB), because of its presence in trace amounts, its dubious metabolism, and a lack of knowledge about its sources. In the present study we determined the distributions of enantiomers of 3-hydroxybutyrate (3HB) in rat brain, liver, heart, and kidney homogenates, and we found the heart homogenate contained an enriched amount of L-3HB (37.67 μM/mg protein) which generated a significant ratio of 66 / 34 (D / L). The ratio was altered to be 87 / 13 in the diabetic rat heart homogenate. We subsequently found this changed ratio of D / L-3HB may contribute to reduce glucose utilization in cardiomyocytes. Glucose utilization by cardiomyocytes with 5 mM of D-3HB was decreased to 61{\%} of the control, but no interference was observed when D-3HB was replaced with L-3HB, suggesting L-3HB is not utilized for the energy fuel as other ketone bodies are. In addition, the reduced glucose utilization caused by D-3HB gradually recovered in a dose-dependent manner with administration of additional L-3HB. The results gave the necessity of taking L-3HB together with D-3HB into account with regard to glucose utilization, and L-3HB may be a helpful substrate for improving inhibited cardiac pyruvate oxidation caused by hyperketonemia.",
keywords = "Cardiomyocytes, D-3-hydroxybutyrate, Glucose utilizaticon, L-3-hydroxybutyrate",
author = "Tsai, {Yih Chiao} and Chou, {Yu Ching} and An-Bang Wu and Chien-Ming Hu and Chen, {Chau Yang} and Chen, {Fu An} and Lee, {Jen Ai}",
year = "2006",
month = "2",
day = "16",
doi = "10.1016/j.lfs.2005.07.013",
language = "English",
volume = "78",
pages = "1385--1391",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Stereoselective effects of 3-hydroxybutyrate on glucose utilization of rat cardiomyocytes

AU - Tsai, Yih Chiao

AU - Chou, Yu Ching

AU - Wu, An-Bang

AU - Hu, Chien-Ming

AU - Chen, Chau Yang

AU - Chen, Fu An

AU - Lee, Jen Ai

PY - 2006/2/16

Y1 - 2006/2/16

N2 - In researches of ketone bodies, D-3-hydroxybutyrate (D-3HB) is usually the major one which has been investigated; in contrast, little attention has been paid to L-3-hydroxybutyrate (L-3HB), because of its presence in trace amounts, its dubious metabolism, and a lack of knowledge about its sources. In the present study we determined the distributions of enantiomers of 3-hydroxybutyrate (3HB) in rat brain, liver, heart, and kidney homogenates, and we found the heart homogenate contained an enriched amount of L-3HB (37.67 μM/mg protein) which generated a significant ratio of 66 / 34 (D / L). The ratio was altered to be 87 / 13 in the diabetic rat heart homogenate. We subsequently found this changed ratio of D / L-3HB may contribute to reduce glucose utilization in cardiomyocytes. Glucose utilization by cardiomyocytes with 5 mM of D-3HB was decreased to 61% of the control, but no interference was observed when D-3HB was replaced with L-3HB, suggesting L-3HB is not utilized for the energy fuel as other ketone bodies are. In addition, the reduced glucose utilization caused by D-3HB gradually recovered in a dose-dependent manner with administration of additional L-3HB. The results gave the necessity of taking L-3HB together with D-3HB into account with regard to glucose utilization, and L-3HB may be a helpful substrate for improving inhibited cardiac pyruvate oxidation caused by hyperketonemia.

AB - In researches of ketone bodies, D-3-hydroxybutyrate (D-3HB) is usually the major one which has been investigated; in contrast, little attention has been paid to L-3-hydroxybutyrate (L-3HB), because of its presence in trace amounts, its dubious metabolism, and a lack of knowledge about its sources. In the present study we determined the distributions of enantiomers of 3-hydroxybutyrate (3HB) in rat brain, liver, heart, and kidney homogenates, and we found the heart homogenate contained an enriched amount of L-3HB (37.67 μM/mg protein) which generated a significant ratio of 66 / 34 (D / L). The ratio was altered to be 87 / 13 in the diabetic rat heart homogenate. We subsequently found this changed ratio of D / L-3HB may contribute to reduce glucose utilization in cardiomyocytes. Glucose utilization by cardiomyocytes with 5 mM of D-3HB was decreased to 61% of the control, but no interference was observed when D-3HB was replaced with L-3HB, suggesting L-3HB is not utilized for the energy fuel as other ketone bodies are. In addition, the reduced glucose utilization caused by D-3HB gradually recovered in a dose-dependent manner with administration of additional L-3HB. The results gave the necessity of taking L-3HB together with D-3HB into account with regard to glucose utilization, and L-3HB may be a helpful substrate for improving inhibited cardiac pyruvate oxidation caused by hyperketonemia.

KW - Cardiomyocytes

KW - D-3-hydroxybutyrate

KW - Glucose utilizaticon

KW - L-3-hydroxybutyrate

UR - http://www.scopus.com/inward/record.url?scp=32044461322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32044461322&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2005.07.013

DO - 10.1016/j.lfs.2005.07.013

M3 - Article

VL - 78

SP - 1385

EP - 1391

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 12

ER -